178 related articles for article (PubMed ID: 35936677)
1. Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.
Grave A; Blanc J; De Bari B; Pernot M; Boulbair F; Noirclerc M; Vienot A; Kim S; Borg C; Boustani J
Front Oncol; 2022; 12():918271. PubMed ID: 35936677
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
[TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.
Kim S; Meurisse A; Spehner L; Stouvenot M; François E; Buecher B; André T; Samalin E; Jary M; Nguyen T; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; de la Fouchardiere C; Boulbair F; Lakkis Z; Klajer E; Jacquin M; Taieb J; Vendrely V; Vernerey D; Borg C
Ther Adv Med Oncol; 2020; 12():1758835920975356. PubMed ID: 33329760
[TBL] [Abstract][Full Text] [Related]
4. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Kim S; Jary M; Mansi L; Benzidane B; Cazorla A; Demarchi M; Nguyen T; Kaliski A; Delabrousse E; Bonnetain F; Letondal P; Bosset JF; Valmary-Degano S; Borg C
Ann Oncol; 2013 Dec; 24(12):3045-50. PubMed ID: 24114858
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
6. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
[TBL] [Abstract][Full Text] [Related]
7. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.
Lee IH; Lee SJ; Kang BW; Chae YS; Baek D; Hwang S; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Kim JG
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1263-1267. PubMed ID: 27830320
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
[TBL] [Abstract][Full Text] [Related]
10. Anti-Telomerase CD4
Spehner L; Kim S; Vienot A; François E; Buecher B; Adotevi O; Vernerey D; Abdeljaoued S; Meurisse A; Borg C
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957741
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial.
Debernardi A; Meurisse A; Prétet JL; Guenat D; Monnien F; Spehner L; Vienot A; Roncarati P; André T; Abramowitz L; Molimard C; Mougin C; Herfs M; Kim S; Borg C
Front Oncol; 2022; 12():941676. PubMed ID: 36313663
[TBL] [Abstract][Full Text] [Related]
12. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.
Eng C; Jácome AA; Das P; Chang GJ; Rodriguez-Bigas M; Skibber JM; Wolff RA; Qiao W; Xing Y; Sethi S; Ohinata A; Crane CH
Clin Colorectal Cancer; 2019 Dec; 18(4):301-306. PubMed ID: 31350201
[TBL] [Abstract][Full Text] [Related]
14. Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma.
Gordeyev SS; Rasulov AO; Gorbounova VA; Tkachev SI; Glebovskaya VV; Fedyanin MY; Besova NS; Surayeva YE
Cancer Chemother Pharmacol; 2017 Sep; 80(3):623-629. PubMed ID: 28766008
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Vendrely V; Ronchin P; Minsat M; Le Malicot K; Lemanski C; Mirabel X; Etienne PL; Lièvre A; Darut-Jouve A; de la Fouchardière C; Giraud N; Breysacher G; Argo-Leignel D; Thimonnier E; Magné N; Abdelghani MB; Lepage C; Aparicio T;
Radiother Oncol; 2023 Sep; 186():109742. PubMed ID: 37315583
[TBL] [Abstract][Full Text] [Related]
16. DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
Kim S; Vendrely V; Saint A; André T; Vaflard P; Samalin E; Pernot S; Bouché O; Zubir M; Desrame J; de la Fouchardière C; Smith D; Ghiringhelli F; Vienot A; Jacquin M; Klajer E; Nguyen T; François É; Taieb J; Le Malicot K; Vernerey D; Meurisse A; Borg C
Exp Hematol Oncol; 2023 Jul; 12(1):63. PubMed ID: 37480095
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
18. Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil.
Voskuilen CS; van de Kamp MW; Schuring N; Mertens LS; Noordzij A; Pos F; van Rhijn BWG; van der Heijden MS; Schaake EE
Radiother Oncol; 2020 Sep; 150():275-280. PubMed ID: 32768507
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
